Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2014; 20(40): 14958-14964
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14958
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14958
Detection of pancreatic cancer with normal carbohydrate antigen 19-9 using protein chip technology
Xiao-Li Jin, Bin Xu, Department of Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang Province, China
Yu-Lian Wu, Department of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China
Author contributions: Jin XL, Xu B and Wu YL performed this research; Wu YL designed the research.
Correspondence to: Yu-Lian Wu, MD, PhD, Professor, Department of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. wuyulian@medmail.com.cn
Telephone: +86-571-87784604 Fax: +86-571-87784604
Received: January 4, 2014
Revised: April 14, 2014
Accepted: June 13, 2014
Published online: October 28, 2014
Processing time: 298 Days and 7.3 Hours
Revised: April 14, 2014
Accepted: June 13, 2014
Published online: October 28, 2014
Processing time: 298 Days and 7.3 Hours
Core Tip
Core tip: Our study focused on patients with malignant disease and normal carbohydrate antigen 19-9 levels who could be easily misdiagnosed clinically. With careful design, our results could provide early diagnostic models to discriminate cancer patients from healthy volunteers or people with benign disease, as well as some potentially important proteins that could serve as tumor/cancer-specific or -associated antigens in future clinical studies.